Here are the 10-K annual reports from Kodiak Sciences Inc (KOD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. files its annual report describing an advanced retinal disease drug pipeline and significant business risks. The company focuses on its Antibody Biopolymer Conjugate platform and three late-stage candidates: Zenkuda (tarcocimab), KSI-501 and KSI-101 for diabetic eye disease, wet AMD, retinal vein occlusion and inflammation-driven macular edema.
Multiple Phase 3 programs, including GLOW1, GLOW2, BEACON and DAYLIGHT, met primary endpoints, while DAYBREAK, PEAK and PINNACLE remain ongoing with topline data expected between 3Q 2026 and 2Q 2027. Kodiak also discloses substantial doubt about its ability to continue as a going concern and highlights dependence on additional financing, regulatory approvals and successful commercialization.